Table 2 Base case results for deterministic and probabilistic analyses: pembrolizumab vs DTIC

Deterministic sensitivity analysis: mean

 Effectiveness (not discounted)

  Progression-free life years

0.61

2.36

1.75

  Post progression life years

2.13

5.48

3.34

  Life years

2.74

7.83

5.09

  QALYs

1.64

6.3

4.7

 Effectiveness discounted

  QALYs

1.64

4.28

2.64

 Costs discounted, $

  Medication costs

10,249

86,937

76,688

  Drug administration costs

959

1693

735

  AE costs

92

863

771

  Additional costs of care

34,779

51,638

16,859

  Total

46,079

141,131

95,052

 Cost effectiveness, $

  Incremental cost per LY gained

18,668

  Incremental cost per QALY gained

35,993

Probabilistic sensitivity analysis: mean (95% class interval)

 Effectiveness discounted

  LYs

2.77 (1.42, 4.41)

7.82 (7.40, 8.21)

5.05 (3.37, 6.49)

  QALYs

1.65 (0.86, 2.59)

4.27 (4.06, 4.48)

2.62 (1.66, 3.46)

 Costs discounted, $

  Total costs

47,124 (35,410, 62,214)

140,612 (127,407, 156,590)

93,488 (80,879, 105,870)

 Cost Effectiveness, $

  Incremental cost per LY gained

18,510 (14,450, 26,412)

  Incremental cost per QALY gained

35,681 (27,509, 53,489)